Flashpoint Therapeutics

What Flashpoint Therapeutics does

Flashpoint Therapeutics is a clinical-stage biotechnology company developing precision-engineered structural nanomedicines for cancer and other diseases. The company is built on a proprietary Spherical Nucleic Acid (SNA) platform developed over the past decade in Chad Mirkin's laboratory at Northwestern University, which enables co-delivery of diverse therapeutic payloads (nucleic acids, peptides, small molecules) with precise stoichiometry and synchronized activation kinetics to target cells. The company serves pharmaceutical partners and research institutions, with active partnerships including KAIMRC (King Abdullah International Medical Research Center) in Saudi Arabia and CancerVax for universal cancer treatment development.

The SNA platform forms the foundation for multiple product candidates across different therapeutic modalities. Current programs include an HPV Cancer Vaccine, an Acute Myeloid Leukemia (AML) nanomedicine, CRISPR-based therapeutics using LNP-SNA delivery technology, and cancer immunotherapy candidates. The company claims technical performance metrics including 650% increased potency over peptide vaccine formulations, 500% improved potency over LNP-encapsulated mRNA, 35x enhanced delivery to immune cells, and 44x improved intracellular co-delivery of Cas9 and sgRNAs. The technology has demonstrated complete remissions in late-stage cancer in clinical studies, with IND-approved candidates manufactured under GMP conditions and supported by peer-reviewed publications in Science Advances.

Flashpoint operates a pre-revenue licensing and co-development business model, generating future revenue through technology licensing agreements and strategic partnerships with pharmaceutical companies. The company has raised approximately $60 million to date through a $10 million seed round led by Beta Lab (October 2023) and a $50 million partnership with KAIMRC (November 2024). Revenue mechanics will derive from licensing royalties, milestone payments, and potential co-development arrangements. The company is privately held, headquartered in the United States, and operates with approximately 10 employees plus a scientific advisory board comprising experts from leading oncology institutions including City of Hope, Harvard, Northwestern, and Fred Hutch Cancer Center.

Name

Flashpoint Therapeutics

Legal name

Flashpoint Therapeutics

Website

https://flashpoint.bio

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

1–10 employees

Short description

Flashpoint Therapeutics is a clinical-stage biotechnology company developing a proprietary Spherical Nucleic Acid (SNA) nanotechnology platform for precision-engineered cancer immunotherapies and other therapeutics, partnering with pharmaceutical companies and research institutions for clinical advancement.

Ownership category

akta.pro rank

Product category

Cancer Nanomedicine

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics) (HLAAADAG)

akta.pro secondary industries

Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches) (HLAAACAF), Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream) (HLAAACAN)

Keywords

• Structural nanomedicines
• Cancer immunotherapy
• Spherical nucleic acids
• Drug delivery platform
• RNA therapeutics

Headquarters

HQ city

Redwood City

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Therapeutic Development and Licensing: Pre-revenue biotech company developing proprietary nanotechnology platform for cancer therapeutics. Revenue generation expected through licensing agreements with pharmaceutical partners, co-development partnerships, and eventual product commercialization.
2. Strategic Partnerships and Collaborations: Partnerships with pharmaceutical companies and research institutions for development and commercialization. Includes co-development agreements like the $50M KAIMRC partnership and CancerVax collaboration for universal cancer treatment.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

Flashpoint Therapeutics develops a proprietary Spherical Nucleic Acid (SNA) structural nanomedicine platform that co-delivers precise combinations of nucleic acids, peptides, proteins, and CRISPR cargo directly to target cells with optimized structure-function relationships and synchronized activation kinetics. The company is advancing a pipeline of first-in-class cancer immunotherapy candidates (HPV cancer vaccine, AML nanomedicine, CRISPR-based therapeutics) through internal development and co-development partnerships with pharmaceutical and research institutions. Revenue is expected to be generated via technology licensing, co-development agreements, and eventual commercialization of therapeutics.

Product overview

Flashpoint Therapeutics is a clinical-stage biotechnology company developing a modular structural nanomedicine platform centered on Spherical Nucleic Acid (SNA) technology. The platform enables precise co-delivery of therapeutic components (mRNA, DNA, peptides, CRISPR) directly to individual cells with optimized structure-function relationships. The company is advancing multiple therapeutic programs including an HPV Cancer Vaccine, Acute Myeloid Leukemia nanomedicine, and CRISPR-based therapeutics, all derived from the core SNA platform. The platform has demonstrated complete remissions in late-stage cancer and has been clinically validated for safety and efficacy.

Differentiator

Problem solved

Functional benefit

Products and services

• Spherical Nucleic Acid (SNA) Platform

Quantifiable outcome

• 650% increased potency over peptide vaccine formulations
• +5 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered flagship and core.

• KAIMRC (King Abdullah International Medical Research Center)flagshipStrategic or Co-development Partner · 14 November 2024$50 million partnership with KAIMRC in Saudi Arabia for clinical pipeline expansion. KAIMRC will host clinical trials for Flashpoint's nanotechnology platform. The partnership includes collaboration on advancing HPV cancer vaccine and other therapeutic candidates toward clinical trials. A MoU was signed in December 2023 for hosting clinical studies.
• Northwestern UniversitycoreTechnology or Integration · 25 October 2023Technology developed at Northwestern University, specifically from the laboratory of Chad Mirkin, Director of the International Institute for Nanotechnology. Scientific co-founders Chad Mirkin, PhD and Michelle Teplensky, PhD originated from Northwestern's research program. Ongoing research collaboration including work on CRISPR delivery improvements.
• CancerVaxcoreStrategic or Co-development PartnerCancerVax entered an agreement with Flashpoint Therapeutics for research on Universal Cancer Treatment platform. CancerVax is utilizing Flashpoint's proprietary nanotechnology platform to drive universal cancer treatment development.

Scale indicators7 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Exicure: Exicure was the original commercial developer of spherical nucleic acid (SNA) technology co-founded by Chad Mirkin, making it the closest historical peer to Flashpoint. Both companies target nucleic acid delivery using SNA architecture for therapeutic applications including oncology and immunology.
• Arcturus Therapeutics: Arcturus develops LNP-based mRNA therapeutics and is advancing multiple oncology and rare disease candidates, making it a directly comparable RNA delivery platform peer. Both companies compete for pharma partnerships around enabling delivery technology for nucleic acid payloads.
• Acuitas Therapeutics: Acuitas is a leading LNP delivery technology provider whose ionizable lipids underpin Moderna's and BioNTech's COVID-19 vaccines. As Flashpoint positions SNA against LNP for nucleic acid delivery, Acuitas represents the leading incumbent delivery platform peer.
• Genevant Sciences: Genevant commercializes LNP and other lipid-based nucleic acid delivery technology developed by Tekmira. As a delivery platform licensor to pharma, Genevant competes with Flashpoint for partnership economics around enabling RNA therapeutics.
• Nanospectra Biosciences: Nanospectra develops gold nanoparticle-based therapeutics (AuroLase) for targeted thermal ablation of solid tumors. As a nanomedicine platform company targeting oncology, it is a directly comparable peer in the structural nanomedicine space.

Emerging players

• Nutcracker Therapeutics: Nutcracker Therapeutics develops a micro-therapeutic delivery platform for RNA medicines with a focus on oncology and rare diseases. Like Flashpoint, it is an emerging platform company enabling therapeutic nucleic acid delivery with proprietary non-viral technology.
• Intellia Therapeutics: Intellia develops CRISPR/Cas9-based gene editing therapies and requires advanced delivery technology (LNP) for in vivo applications. As Flashpoint demonstrates superior CRISPR delivery via LNP-SNAs, Intellia represents a potential customer and adjacent platform peer.
• Strand Therapeutics: Strand develops self-replicating and programmable mRNA therapeutics with controllable expression profiles, primarily for oncology. Like Flashpoint, it is an emerging RNA therapeutics platform targeting cancer with proprietary delivery innovations.
• MiNA Therapeutics: MiNA develops saRNA (small activating RNA) therapeutics with a lead oncology candidate in clinical development. As an emerging RNA therapeutics platform peer, MiNA shares with Flashpoint the challenge of partnering or independently commercializing novel RNA-based mechanisms.

Broad incumbents

• Moderna: Moderna is the dominant LNP-mRNA platform company with multiple approved products and a broad oncology pipeline. While operating at vastly greater scale, Moderna represents the broad incumbent benchmark against which all mRNA/nucleic acid delivery platforms are evaluated.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/flashpoint-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles20 records

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Flashpoint Therapeutics